BCR and chronic myelogenous leukemia, BCR-ABL1 positive: The treatment for chronic myelogenous leukemia (CML), imatinib, selectively deactivates a mutant tyrosine kinase called BCR–ABL, which is encoded by the fusion of two genes.437